

<i>Highly Specialised Technologies (HST)</i>	<i>Date of HST Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication Yes OR No</i>	<i>Reason provided if "No"</i>
2019-20			
HST9 - Inotersen for treating hereditary transthyretin amyloidosis	22/05/2019	No	Not applicable to CWFT - not commissioned
HST10 - Patisiran for treating hereditary transthyretin amyloidosis	14/08/2019	No	Not applicable to CWFT - not commissioned
HST11- Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations	09/10/2019	No	Not applicable to CWFT - not commissioned
HST12 - Cerliponase alfa for treating neuronal ceroid lipofuscinosis Type 2	27/11/2019	No	Not applicable to CWFT - not commissioned